Abstract Library

#3885 Adaptive immunosuppressive resistance mechanisms towards antiangiogenic immunotherapies revealed in a pancreatic neuroendocrine tumor (PNET) model

Introduction: Pancreatic neuroendocrine tumors (PNETs) are mostly indolent but can achieve malignancy. Surgery is the only approved first-line therapy. Kinase inhibitors and radiotherapy for unresectable PNETs are non-curative and targeted therapies are currently lacking for PNETs. However, immune checkpoint inhibitors have created a paradigm shift in cancer therapy with significant increase in overall survival, but are curative only in a subset of patients, partly due to limited T cell infiltration, especially in angiogenic and cold tumors like PNETs. Parallelly, antiangiogenic therapy increases lymphocyte infiltration by normalising the tumor vasculature. Tallying antiangiogenic to immunotherapies (AI) has provided improved survival benefits for patients of advanced RCCs and HCCs, while other cancers like glioblastoma remain highly resistant.

Conference:

Presenting Author:

Authors: John Robbert D, Guyot M, Killian T, Verslype C, Lambrechts D,

Keywords: Pancreatic neuroendocrine tumor, Antiangiogenic immunotherapy, single cell transcriptomics, Immunosuppression,

#3361 FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors

Introduction: Well-differentiated neuroendocrine tumors (NETs) are relatively rare, highly vascularized neoplasms. Antiangiogenic drugs have shown efficacy in patients with advanced NETs. Bevacizumab is a well-known antiangiogenic monoclonal antibody.

Conference:

Presenting Author:

Authors: Lacombe C, Perrier M, Hentic O, Brixi H, Rebours V,

Keywords: neuroendocrine tumor, antiangiogenic therapy, VEGF, well-differentiated,

#1179 A Phase II Study of Axitinib in Advanced Carcinoid Tumors: Preliminary Results

Introduction: NETs are highly vascularized neoplasms overexpressing VEGF as well as VEGFR. Axitinib is a TKI with selective picomolar potency against VEGFR-1, -2 and -3

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Cives M, Strosberg J, Campos T, Weber T, Nickerson M,

Keywords: axitinib, anti-angiogenesis, VEGFR,

#744 Bio-Differentiating and Antiangiogenic Therapy with Gastroenteropancreatic Patients with Neuroendocrine Tumors (GEP-NETs)

Introduction: The outcome of patients with metastatic, progressive or recurrent neuroendocrine tumors remains poor despite the several novel therapeutic approaches.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Holubec L

Authors: Holubec L, Finek J, Fiala O, Matejka V, Dreslerova J,

Keywords: GEP-NET, experimental metronomic therapy, tumor marker,

#211 Phase II Study of Sunitinib Following Hepatic Transarterial Embolization for Metastatic Neuroendocrine Tumors

Introduction: Hepatic transarterial embolization is often recommended for patients with liver-predominant metastatic NETs. Antiangiogenic therapy following embolization may delay tumor revascularization.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Strosberg J, Cheema A, Campos T, Kvols L,

Keywords: transarterial embolization, sunitinib, progression-free survival,